Navalign LLC Has $923,000 Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Navalign LLC cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,739 shares of the medical research company’s stock after selling 212 shares during the period. Navalign LLC’s holdings in Thermo Fisher Scientific were worth $923,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Halpern Financial Inc. boosted its position in shares of Thermo Fisher Scientific by 307.7% in the third quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 40 shares during the period. Coppell Advisory Solutions LLC acquired a new position in Thermo Fisher Scientific in the second quarter valued at about $33,000. Live Oak Investment Partners bought a new position in Thermo Fisher Scientific in the 4th quarter valued at about $36,000. Tyler Stone Wealth Management acquired a new position in Thermo Fisher Scientific during the second quarter valued at approximately $37,000. Finally, Indiana Trust & Investment Management CO bought a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at $38,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock worth $28,513,384 in the last three months. 0.32% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on TMO shares. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Wolfe Research began coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $575.00 price objective for the company. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective on the stock. Royal Bank of Canada increased their price target on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, Robert W. Baird restated an “outperform” rating and set a $670.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, December 14th. Five equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $599.00.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO traded up $1.84 during mid-day trading on Thursday, hitting $581.21. The company had a trading volume of 1,034,640 shares, compared to its average volume of 1,617,943. The stock’s 50-day moving average price is $565.13 and its 200-day moving average price is $520.22. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The company has a market capitalization of $221.62 billion, a price-to-earnings ratio of 37.63, a P/E/G ratio of 2.39 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. During the same period in the prior year, the business earned $5.40 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was down 4.9% compared to the same quarter last year. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be issued a dividend of $0.39 per share. The ex-dividend date is Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.